ABOS — Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.

Company profile

• Sector: Healthcare
• Industry: Biotechnology
• Country: US
• Exchange: NASDAQ
• Employees: 61
• Website: https://acumenpharm.com

Latest SEC filings for ABOS

• 8-K — 2026-09-16
• S-8 — 2026-08-12
• 8-K — 2026-08-12
• 10-Q — 2026-08-12
• 8-K — 2026-06-16
• 10-Q — 2026-05-12
• 8-K — 2026-05-12
• ARS — 2026-04-23
• EFFECT — 2026-04-02
• 424B3 — 2026-04-01

Abrir análisis completo

Educational tool only — not investment advice.